1. Novel Elongator Protein 2 Inhibitors Mitigating Tumor Necrosis Factor
- Author
-
Wen-Jiao, Wu, Chang-Liang, Xia, Shuan-Ji, Ou, Yang, Yang, Yun-Fei, Ma, Yi-Long, Hou, Qing-Po, Yang, Jun, Zhang, Jian-Wei, Li, Yong, Qi, and Chang-Peng, Xu
- Subjects
Genetic Markers ,Models, Molecular ,Osteoblasts ,Databases, Pharmaceutical ,Tumor Necrosis Factor-alpha ,Drug Evaluation, Preclinical ,Intracellular Signaling Peptides and Proteins ,Cell Differentiation ,3T3 Cells ,In Vitro Techniques ,Surface Plasmon Resonance ,Ligands ,Cell Line ,Molecular Docking Simulation ,Mice ,Structure-Activity Relationship ,User-Computer Interface ,Calcification, Physiologic ,Osteogenesis ,Animals ,Protein Binding ,Research Article - Abstract
Tumor necrosis factor-α is a common cytokine that increases in inflammatory processes, slows the differentiation of bone formation, and induces osteodystrophy in the long-term inflammatory microenvironment. Our previous study confirmed that the Elongation protein 2 (ELP2) plays a significant role in osteogenesis and osteogenic differentiation, which is considered a drug discovery target in diseases related to bone formation and differentiation. In this study, we applied an in silico virtual screening method to select molecules that bind to the ELP2 protein from a chemical drug molecule library and obtained 95 candidates. Then, we included 11 candidates by observing the docking patterns and the noncovalent bonds. The binding affinity of the ELP2 protein with the candidate compounds was examined by SPR analysis, and 5 out of 11 compounds performed good binding affinity to the mouse ELP2 protein. After in vitro cell differentiation assay, candidates 2# and 5# were shown to reduce differentiation inhibition after tumor necrosis factor-α stimulation, allowing further optimization and development for potential clinical treatment of inflammation-mediated orthopedic diseases.
- Published
- 2021